Canaccord analyst Kyle Mikson lowered the firm’s price target on Repligen (RGEN) to $150 from $170 and keeps a Hold rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen price target lowered to $202 from $219 at RBC Capital
- Repligen appoints Jacob Johnson as VP, investor relations
- Promising Outlook for Repligen: Strong Order Momentum, Strategic Positioning, and Growth Opportunities
- Repligen initiated with an In Line at Evercore ISI
- Repligen’s Strategic Acquisition of 908 Devices’ Assets: A Buy Rating for Long-term Shareholder Value